references
RESEARCH
Through compound screening, lead selection, and lead optimization, the objective of DNDi’s research programme is to identify new drug candidates that meet the criteria described in each disease’s target product profile for entry into the pre-clinical development process.
SCREENING
Overall objective: Identification of new active compounds via medium to high throughput screening assays in dedicated centres: High throughput screening (large-size libraries) • for leishmaniasis (Leishmania) and Chagas disease (Trypanosoma cruzi )
The Institut Pasteur Korea, South Korea, and the Drug Discovery Unit, University of Dundee, UK
Screening for kinetoplastids (leishmaniasis, Chagas disease, HAT) Objective: Establish a robust portfolio of drug discovery quality hits for the three kinetoplastid diseases, with a focus on VL and Chagas disease. Main compound libraries:
Screening of repurposing libraries for filarial diseases Objective: Identify new drug candidates using targeted compounds, primarily from repurposing libraries from human and animal health companies. Main compound libraries:
Medium throughput screening • for kinetoplastids (leishmaniasis, Chagas disease, and HAT (Trypanosoma brucei )
The Swiss Tropical and Public Health Institute, Switzerland; the Laboratory of Microbiology, Parasitology, and Hygiene, University of Antwerp, Belgium; and the Walter Reed Army Institute of Research, USA
AbbVie, USA; Anacor Pharmaceuticals Inc., USA; Astellas Pharma, Japan; AstraZeneca, UK; Celgene, USA; Daiichi Sankyo, Japan; Eisai Co. Ltd, Japan; GlaxoSmithKline, Tres Cantos, Spain; Institut Pasteur Korea, South Korea; London School of Hygiene and Tropical Medicine (LSHTM), UK; Medicines for Malaria Venture (MMV), Switzerland; Merck, USA; Microbial Chemistry Research Foundation, Japan; Pfizer Ltd, UK; University of Dundee, UK; Sanofi, France; Takeda Pharmaceutical Company Ltd, Japan; TB Alliance, USA
AbbVie, USA; AstraZeneca, UK; BASF, Germany; Bristol-Myers Squibb, USA; Celgene, USA; GlaxoSmithKline, Tres Cantos, Spain; E.I. DuPont Nemours, USA; Epichem, Australia; Janssen, Belgium; Mercachem, The Netherlands; Merck, USA; Merck Serono, Germany; Medicines for Malaria Venture, Switzerland; National Institutes of Health, USA; Novartis Centre de la Recherche Santé Animale, Switzerland; Sanofi, France; TB Alliance, USA; WuXi AppTech, China
LEISHMANIASIS CHAGAS DISEASE
• for filarial diseases
The Hospital of Bonn, Institute for Medical Microbiology, Immunology & Parasitology, Germany; the Muséum National d’Histoire Naturelle Paris, France; and the Northwick Park Institute for Medical Research, UK
NTD Drug Discovery Booster
In parallel to its ongoing bilateral collaborations for screening and lead optimization, in 2015 DNDi launched the NTD Drug Discovery Booster with several major pharmaceutical companies. Objective: Identify promising new compounds for treatment of leishmaniasis and Chagas disease by using a multilateral, simultaneous search process across several global pharmaceutical companies. The booster allows DNDi to access millions of unique compounds, generated over many decades of research, to screen for potential treatments or cures for these diseases. Main partners: AstraZeneca, UK; Celgene, USA; Eisai, Japan; Shionogi, Japan; Takeda Pharmaceutical Company Ltd,
Japan
8
• R&D Portfolio
